Recently, a Jiangxi Fushine Pharmaceutical Co.Ltd(300497) (300497) company has staged a wave of textbook “roller coaster” market for investors.
First, a large number of positive news came out through social platforms, interactive platforms and other channels, and the company’s share price rose all the way. Then the news came to an abrupt end. The company’s share price also changed from the 20cm limit to a sudden sharp decline until “halving”. What makes investors feel even more strange is that on the day before the sharp decline, the top ranked shareholders of the company also happened to “accurately reduce their holdings”
notice of stock price change
Briefly describe the share price of Jiangxi Fushine Pharmaceutical Co.Ltd(300497) , that is, the company’s share price suddenly continued to rise from January 12 to 17, and closed the 20cm limit on January 19. During the period of , increased by 49% .
However, just after the 20cm limit was closed on the 20th, the company’s share price quickly changed from red to green, closed down 7.31%, and fell continuously in the next few days, with a cumulative decline of 46%. Compared with the high of nearly 29.4 yuan / share on the 20th, directly “cut back” .
\u3000\u3000
To what extent is this stock price fluctuation exaggerated? On January 24 and 26, Jiangxi Fushine Pharmaceutical Co.Ltd(300497) successively issued the announcement of abnormal fluctuations in stock trading, the supplementary announcement of abnormal fluctuations in stock trading and the announcement of serious abnormal fluctuations in stock trading, reminding investors to “invest rationally and pay attention to risks”.
On 27, the Shenzhen Stock Exchange also sent a letter of concern to Jiangxi Fushine Pharmaceutical Co.Ltd(300497) . the regulator pointed out that the stock price of Jiangxi Fushine Pharmaceutical Co.Ltd(300497) fluctuated greatly from January 19 to January 26, 2022. The stock price rose by the limit on January 19, and then continued to fall. During this period, it touched the abnormal fluctuation of stock trading on January 24 and the serious abnormal fluctuation of stock trading on January 26.
so, is the sharp fluctuation of Jiangxi Fushine Pharmaceutical Co.Ltd(300497) stock price really just because investors don’t “invest rationally and pay attention to risks”? The Shenzhen Stock Exchange does not seem to think so.
According to the attention letter, Jiangxi Fushine Pharmaceutical Co.Ltd(300497) during the change of stock price, investors repeatedly asked questions on the interactive platform of Shenzhen Stock Exchange to pay attention to the business related to the company’s supply of core intermediates of mopiravir and redcivir to customers. Therefore, the company is required to explain the product name, purpose, R & D and production investment, market share On hand orders, major customers, etc., and explain to verify whether it is suspected of misleading investors and whether there are misleading statements.
At the same time, Jiangxi Fushine Pharmaceutical Co.Ltd(300497) disclosed the lithium battery additive project and other relevant information in the record of investor relations activities on January 19. Therefore, the company is required to supplement the specific information of the business involved in the field of lithium battery additive products and explain the specific impact of on the company’s future financial situation and operating results after the project is put into operation, and fully prompt the risk.
as questioned by the Shenzhen Stock Exchange, during the ups and downs of Jiangxi Fushine Pharmaceutical Co.Ltd(300497) stock price, various news related to it also seems to be flying everywhere.
For example, the company’s most concerned “covid-19 specific drug intermediate” news: as early as January 6, the company replied to investors on the interactive easy platform that “the product can not be used for covid-19 therapeutic drugs”; However, when replying to investors on the 14th, it turned into “kilogram samples have been supplied to customers”; Later, the company also said that the intermediate products supplied were “the core intermediate of mupiravir and redcivir”. However, when asked whether mupiravir is the covid-19 oral specific antiviral oral drug molnupiravir (monapiravir) of MSD, the company replied that it was inconvenient to disclose
However, on January 19, the company suddenly told investors that “it has rich experience in the production of antiviral intermediates and strong commercial production capacity, and has the R & D and production capacity of covid-19 therapeutic drug intermediates. It is expected to enter the supply chain system of covid-19 therapeutic drug production of Pfizer and other companies.” On this day, the company ushered in the first trading limit in 2022.
shareholders’ cash out in advance
retail connection…
Coincidentally, during the rollercoaster of the stock price, the shareholders of the company happened to reduce their holdings at high prices, and even the time of reduction was “accurate ” the day before the sharp decline.
On the evening of January 19, Jiangxi Fushine Pharmaceutical Co.Ltd(300497) announced that the company received the notice on the progress of reducing our holdings of Jiangxi Fushine Pharmaceutical Co.Ltd(300497) shares issued by the shareholder Zhejiang Yongtai Technology Co .Ltd(002326) .
According to the notice, Zhejiang Yongtai Technology Co .Ltd(002326) reduced 5.4156 million shares of the company through centralized bidding on January 13, 2022 and January 19, 2022, accounting for 1.00% of the total share capital of the company after excluding the repurchase of social public shares, and more than half of the reduction. Among them, 2908591 shares were reduced on January 13, about 53.02 million yuan; On January 19, 2507040 shares were reduced, about 53.4 million yuan. The cumulative reduction amount of exceeded 100 million yuan .
\u3000\u3000
At the same time, the actual controller, who issued a notice saying that it was “ready to increase its holdings”, seemed to have just increased its holdings to a low point. According to the previous increase announcement, company’s actual controller, chairman Bao Jianhua and his spouse Ke Dan plan to increase their holdings by no less than 50 million yuan and no more than 100 million yuan.
On January 26, the company announced that Ke Dan increased his holdings of 1265400 shares at an average price of 15.82 yuan / share on January 25. Previously, the amount was no less than 50 million yuan, and Ke Dan has completed more than 38 million yuan.
What’s more amazing is that the company also issued a announcement on short-term trading and apology of relatives of senior executives of the company on January 18, saying that the spouses of senior executives of the company bought and sold the company’s shares on January 14, 2022 and January 17, 2022 respectively, involving hundreds of thousands of yuan of trading amount and a profit of about 16000 yuan, which constituted a short-term transaction. Fortunately, the relevant personnel actively cooperated Take the initiative to correct, have handed over the proceeds of this short-term exchange to the company, and sincerely apologize to the majority of investors.
it’s just that the shareholders who “happen” to reduce their holdings at a high level have made a lot of money, and the boss’s wife who released the announcement of increasing their holdings is also “increasing” their holdings at a low point. Even the company has made a small profit of more than 10000 because of the short-term transactions that the executive spouse happens to appear… The remaining retail investors seem not so happy.
On January 26, the data disclosed by the Shenzhen Stock Exchange showed that Jiangxi Fushine Pharmaceutical Co.Ltd(300497) fell by 46% from January 20 to January 26. During the period, natural persons bought a total of 10.157 billion yuan, accounting for 86.59% ; Among them, small and medium-sized investors bought 4.994 billion yuan, accounting for 42.57% . Institutions bought a total of 1.305 billion yuan, accounting for 11.12% .
In other words, the ups and downs of the stock price were thoroughly revealed. During this period, few institutions bought the stock, and those who became “disk takers” were basically hot money and small scattered funds.
